相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study
Jose Luis Rodriguez-Garcia et al.
RHEUMATOLOGY (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
A. D'Alessio et al.
LEUKEMIA (2021)
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
Justin Stebbing et al.
SCIENCE ADVANCES (2021)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Fabrizio Cantini et al.
JOURNAL OF INFECTION (2020)
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
Valentina Giudice et al.
FRONTIERS IN PHARMACOLOGY (2020)
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
Fabrizio Cantini et al.
JOURNAL OF INFECTION (2020)
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
F. Heidel et al.
LEUKEMIA (2020)
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
Andreas Neubauer et al.
LEUKEMIA (2020)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
F. La Rosee et al.
LEUKEMIA (2020)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
Alessandro Gozzetti et al.
LEUKEMIA (2020)
Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study
Marco Falcone et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
José Rosas et al.
Reumatologia Clinica (2020)
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Vincenzo Bronte et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
分享论文
